Close
Top Videos
Top Searches
Moods
Black Lives Matter
Chill
Christmas
Commute
Energy boosters
Feel-Good
Focus
Party
Pride
Romance
Sad
Sleep
Workout
Genres
African
Arabic
Blues
Bollywood & Indian
Christian & Gospel
Classical
Country and Americana
Dance and electronic
Decades
Family
Folk and acoustic
Hip-hop
Indie and alternative
J-Pop
Jazz
K-Pop
Latin
Mandopop & Cantopop
Metal
Pop
R&B and Soul
Reggae and Caribbean
Rock
Soundtracks and musicals
Overcoming challenges with targeted therapies for CLL: high-risk mutations and BTKi resistance
03:08
|
Download MP3
Related Videos
5:11
iStopMM: the psychological effects of MGUS screening and changes to clinical presentation of myeloma
3:08
Welcome to the Video Journal of Hematology & Hematological Oncology 🎥🩸
2:22
The need for novel agents to treat patients with MCL who have relapsed after targeted therapy
2:14
A new classification for identifying high-risk myeloma based on cytogenetic abnormalities
4:48
The evolution of alloSCT in Richter's transformation and its combination with biological agents
1:31
Frontline treatment for CLL: the changing paradigm
1:36
The use of outpatient cilta-cel in the treatment of multiple myeloma
3:24
The impact of biological sex in sickle cell disease
1:32
Unanswered questions in MCL: when will we achieve cure?
2:57
Moving away from chemoimmunotherapy and towards novel targeted agents in CLL
2:13
Personalizing the timing of SCT in patients with myelofibrosis
1:14
Promising therapies under investigation in AL amyloidosis: anti-fibril agents & bispecifics
2:26
An insight into the aims of the Eurasian Hematology-Oncology Group
1:20
Insights into the diagnosis of smoldering myeloma from a UK perspective & ongoing trials
2:55
A model including CD49d expression to predict outcomes in patients with CLL treated with ibrutinib
1:13
Molecular MRD as a prognostic marker for AML patients with mutated CEBPA
3:48
Trials of interest in newly diagnosed myeloma presented at IMS 2024
6:54
Biomarker-guided treatment of CLL in the chemo-free era
1:01
Treatment-free remission after second-generation TKI treatment in CML
2:19
The addition of venetoclax to hyper-CVAD-nelarabine and pegylated asparagine in T-ALL
5:11 3:08 2:22 2:14 4:48 1:31 1:36 3:24 1:32 2:57 2:13 1:14 2:26 1:20 2:55 1:13 3:48 6:54 1:01 2:19
